MIT researchers have developed a technique that transforms immune cells into cancer fighters directly inside the body, potentially making advanced immunotherapies much simpler and less expensive to produce.
The method uses tiny lipid nanoparticles to deliver messenger RNA instructions to natural killer (NK) cells, directing them to produce specialised receptors that help identify and eliminate diseased cells. The resulting engineered cells, known as CAR NK cells, could eventually treat several different cancers and autoimmune conditions.
Current CAR T cell therapies require extracting immune cells from patients, modifying them in specialised laboratories, growing sufficient quantities, and returning them for infusion. This complex manufacturing process is time-consuming and costly. By engineering NK cells directly inside the body, the new approach could bypass much of this complexity.
Natural killer cells offer an additional advantage over T cells for certain applications. When treating T cell cancers or autoimmune diseases involving harmful T cells, using CAR T cells creates a problem: the engineered cells may attack one another. NK cells, being a different cell type, avoid this complication.
In mouse experiments published in Nature Biotechnology, the researchers successfully modified approximately 80% of targeted NK cells after nanoparticle injection. Three of five mice with aggressive melanoma achieved complete remission, whilst tumours were completely eliminated in a humanised mouse model of T-cell lymphoma after five injections.
The technique also showed promise for autoimmune conditions. A single injection reversed liver damage in mice with autoimmune hepatitis by eliminating the harmful T cells attacking liver tissue.
Further research will determine whether the approach is safe and effective in humans.
Source: Chen Y et al. In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. Nature Biotechnology (2026). DOI: 10.1038/s41587-026-03310-1